Newswise — Therapeutics for Alzheimer’s disease are most likely to work if started early in the disease’s course, when amyloid plaques accumulate in the brain but memory is still intact. In their quest to recruit subjects in this preclinical disease state, clinicians must test people for AD risk factors such as brain amyloid accumulation or ApoE genotype, and then disclose that information to them so they can enroll in a trial. At the Alzheimer's Association International Conference, researchers presented early findings regarding the ethical, psychological, and societal impacts of such disclosure, and laid out their plans for the best ways to deliver the information. Cancer risk disclosure is more advanced, and guides their way. Beyond clinical trials, having smart disclosure procedures in place will be crucial if an AD therapy is approved, as then scores of people will want to get tested to head off the disease. Jessica Shugart examines the dilemma.
About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.